Gastric cancer continues to be a lethal disease globally. In spite of a recent increase in available systemic therapeutics, the prognosis of patients with advanced disease remains poor. However, a number of targeted therapies have been evaluated in gastric cancer, albeit with mixed results. Ramucirumab is the first anti-angiogenic agent to treat patients with advanced or metastatic gastric cancers.
The current article highlights the use of ramucirumab in gastric can cer. Gastric cancer accounts for fourth most common malignancy in men and the fifth most common malignancy in women. The cure for the condition is possible for the patients who are presenting with an early stage disease where surgical resection can be combined with adjuvant chemotherapy with or without radiotherapy. Improved outcomes usually involve a multidisciplinary approach using chemotherapy in conjunction with surgery.…
